Shukui Qin

机构：China Pharmaceutical University, Jiangsu Cancer Hospital, Jinling Institute of Technology · ORCID：0000-0003-2289-1521

发表论文 558 篇 · 总被引 52153 次 · h-index 76

代表论文

• Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial (2025 · Blood · 被引 2)
• Cancer-associated fibroblasts expressing FSTL3 promote vasculogenic mimicry formation and drive colon cancer malignancy (2025 · Cell Death and Disease · 被引 2)
• Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study (2025 · Therapeutic Advances in Medical Oncology · 被引 2)
• An aggregation-induced emission-active theranostic agent for selectively detecting and intervening pathological Tau protein (2025 · Journal of Materials Chemistry B · 被引 1)
• First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial (2025 · European Journal of Cancer · 被引 1)
• Safety and pharmacokinetics evaluation of oroxylin A in Chinese healthy volunteers: a phase I, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect study (2025 · Clinical & Translational Oncology · 被引 1)